As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
16 Analysts have issued a Otsuka Holdings forecast:
16 Analysts have issued a Otsuka Holdings forecast:
Jun '25 |
+/-
%
|
||
Revenue | 2,401,697 2,401,697 |
10%
10%
|
|
Gross Profit | 1,732,051 1,732,051 |
12%
12%
|
|
EBITDA | 537,834 537,834 |
17%
17%
|
EBIT (Operating Income) EBIT | 428,099 428,099 |
21%
21%
|
Net Profit | 408,854 408,854 |
222%
222%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. It operates through the following business segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. Its products include Bon Curry, Mannan Hikari, and ReSOLA. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded in1950 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Makoto Inoue |
Employees | 35,338 |
Founded | 1921 |
Website | www.otsuka.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.